MX2015011951A - Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas. - Google Patents

Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas.

Info

Publication number
MX2015011951A
MX2015011951A MX2015011951A MX2015011951A MX2015011951A MX 2015011951 A MX2015011951 A MX 2015011951A MX 2015011951 A MX2015011951 A MX 2015011951A MX 2015011951 A MX2015011951 A MX 2015011951A MX 2015011951 A MX2015011951 A MX 2015011951A
Authority
MX
Mexico
Prior art keywords
fusion proteins
pdgf
methods
binding portions
vegf binding
Prior art date
Application number
MX2015011951A
Other languages
English (en)
Other versions
MX363533B (es
Inventor
Abraham Scaria
Samuel Wadsworth
Peter Pechan
Jeffrey Ardinger
Hillard Rubin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2015011951A publication Critical patent/MX2015011951A/es
Publication of MX363533B publication Critical patent/MX363533B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente invención proporciona proteínas de fusión que comprenden partes de unión a PDGF y VEGF, y partículas virales recombinantes que codifican las proteínas de fusión. También se proporcionan composiciones que comprenden las proteínas de fusión y partículas virales así como métodos para usarlas.
MX2015011951A 2013-03-13 2014-03-13 Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas. MX363533B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780914P 2013-03-13 2013-03-13
PCT/US2014/026872 WO2014160507A1 (en) 2013-03-13 2014-03-13 Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof

Publications (2)

Publication Number Publication Date
MX2015011951A true MX2015011951A (es) 2016-04-07
MX363533B MX363533B (es) 2019-03-27

Family

ID=50680144

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011951A MX363533B (es) 2013-03-13 2014-03-13 Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.

Country Status (27)

Country Link
US (4) US9637534B2 (es)
EP (1) EP2968461B1 (es)
JP (2) JP6561042B2 (es)
KR (1) KR102228921B1 (es)
CN (1) CN105188733B (es)
AR (1) AR095437A1 (es)
AU (2) AU2014243712B2 (es)
BR (1) BR112015022208A8 (es)
CA (1) CA2904623A1 (es)
DK (1) DK2968461T3 (es)
ES (1) ES2933558T3 (es)
FI (1) FI2968461T3 (es)
HK (1) HK1220618A1 (es)
HR (1) HRP20221447T1 (es)
HU (1) HUE060464T2 (es)
IL (2) IL240950B (es)
LT (1) LT2968461T (es)
MX (1) MX363533B (es)
PL (1) PL2968461T3 (es)
PT (1) PT2968461T (es)
RS (1) RS63820B1 (es)
RU (1) RU2692652C2 (es)
SG (3) SG10201912956YA (es)
SI (1) SI2968461T1 (es)
TW (1) TWI631133B (es)
UY (1) UY35407A (es)
WO (1) WO2014160507A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
KR102228921B1 (ko) 2013-03-13 2021-03-16 젠자임 코포레이션 Pdgf 및 vegf 결합 부분을 포함하는 융합 단백질 및 이의 이용방법
US20160137717A1 (en) * 2013-06-20 2016-05-19 Gabriela Burian Use of a vegf antagonist in treating choroidal neovascularisation
EP3041513B1 (en) 2013-09-08 2020-08-05 Kodiak Sciences Inc. Factor viii zwitterionic polymer conjugates
KR101819135B1 (ko) 2014-03-18 2018-01-18 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질
WO2015200905A2 (en) * 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN107208076A (zh) 2014-10-17 2017-09-26 科达制药 丁酰胆碱酯酶两性离子聚合物缀合物
US11299531B2 (en) 2015-03-11 2022-04-12 Allgenesis Biotherapeutics Inc. Fusion protein comprising a ligand binding domain of VEGF and PDGF
JP6655718B2 (ja) * 2015-06-28 2020-02-26 オールジェネシス バイオセラピューティクス インコーポレイテッド 血管新生を阻害するための融合タンパク質
EP3377101A4 (en) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. VEGF BINDING METHODS AND COMPOSITIONS
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017172853A1 (en) 2016-03-30 2017-10-05 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
JP6849390B2 (ja) * 2016-10-28 2021-03-24 花王株式会社 関節のこわばり改善剤
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
WO2019083171A2 (ko) * 2017-10-26 2019-05-02 주식회사 큐로진생명과학 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물
US11548931B2 (en) 2017-11-16 2023-01-10 Xl-Protein Gmbh PASylated VEGFR/PDGFR fusion proteins and their use in therapy
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
US11524053B2 (en) * 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
US20230024569A1 (en) * 2019-12-04 2023-01-26 Cdmogen Co., Ltd. Composition for treating diabetic retinopathy, comprising raav containing soluble vegfr-1 variant cdna
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN113105558A (zh) * 2021-04-01 2021-07-13 芜湖英特菲尔生物制品产业研究院有限公司 一种酿酒酵母表达人rPDGF-HSA融合蛋白及其标准品的制备方法
EP4355767A1 (en) * 2021-06-18 2024-04-24 Ikarovec Limited Retinal disorders
WO2023199951A1 (ja) * 2022-04-13 2023-10-19 株式会社セルージョン 抗ｖｅｇｆ機能を有する多能性幹細胞及びその分化細胞
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
WO2024029876A1 (ko) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4952515A (en) 1987-05-22 1990-08-28 Polymer Technology International Corp. Method of detection using a test strip having a non particulate dialyzed polymer layer
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
AU1411092A (en) 1991-01-31 1992-09-07 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2308989T3 (es) 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE60117550T2 (de) 2000-06-01 2006-12-07 University Of North Carolina At Chapel Hill Doppelsträngige parvovirus-vektoren
US20030181531A1 (en) 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
AU2003218168A1 (en) 2002-03-15 2003-09-29 University Of Southern California Ophthalmic solutions for delivery of expression vectors
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
ES2347340T3 (es) 2004-09-13 2010-10-28 Genzyme Corporation Construcciones multimericas.
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
DE102005020510A1 (de) 2005-04-29 2006-11-09 Basf Ag Verbundelement, insbesondere Fensterscheibe
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN101951925A (zh) 2008-02-20 2011-01-19 建新公司 血管发生抑制
EP2604279A1 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
CN102311502B (zh) * 2010-07-10 2013-12-25 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其医疗应用
AU2011336592A1 (en) * 2010-12-02 2013-07-11 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
CN105949313B (zh) 2011-03-29 2021-06-15 罗切格利卡特公司 抗体Fc变体
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
KR102228921B1 (ko) 2013-03-13 2021-03-16 젠자임 코포레이션 Pdgf 및 vegf 결합 부분을 포함하는 융합 단백질 및 이의 이용방법

Also Published As

Publication number Publication date
ES2933558T3 (es) 2023-02-10
US9637534B2 (en) 2017-05-02
UY35407A (es) 2014-10-31
LT2968461T (lt) 2022-12-27
FI2968461T3 (fi) 2023-01-13
US20170342127A1 (en) 2017-11-30
CN105188733B (zh) 2020-05-08
JP6561042B2 (ja) 2019-08-14
IL240950B (en) 2019-06-30
CN105188733A (zh) 2015-12-23
SI2968461T1 (sl) 2023-01-31
US20190345223A1 (en) 2019-11-14
SG10201707501TA (en) 2017-10-30
RU2692652C2 (ru) 2019-06-25
US11084864B2 (en) 2021-08-10
IL240950A0 (en) 2015-11-30
US20220064262A1 (en) 2022-03-03
BR112015022208A2 (pt) 2017-10-10
IL266715A (en) 2019-07-31
JP2019123711A (ja) 2019-07-25
JP2016513669A (ja) 2016-05-16
HRP20221447T1 (hr) 2023-01-20
SG10201912956YA (en) 2020-02-27
PL2968461T3 (pl) 2023-01-30
AU2014243712B2 (en) 2018-09-13
AU2018278902A1 (en) 2019-01-03
RU2015142999A (ru) 2017-04-17
US10183983B2 (en) 2019-01-22
BR112015022208A8 (pt) 2018-01-23
US20140315804A1 (en) 2014-10-23
TW201506038A (zh) 2015-02-16
MX363533B (es) 2019-03-27
EP2968461B1 (en) 2022-09-21
HK1220618A1 (zh) 2017-05-12
AU2014243712A1 (en) 2015-10-15
AR095437A1 (es) 2015-10-14
WO2014160507A1 (en) 2014-10-02
EP2968461A1 (en) 2016-01-20
KR20150126923A (ko) 2015-11-13
PT2968461T (pt) 2022-12-26
HUE060464T2 (hu) 2023-03-28
DK2968461T3 (da) 2022-12-19
RS63820B1 (sr) 2023-01-31
CA2904623A1 (en) 2014-10-02
SG11201506802SA (en) 2015-09-29
TWI631133B (zh) 2018-08-01
KR102228921B1 (ko) 2021-03-16

Similar Documents

Publication Publication Date Title
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
HK1253065A1 (zh) 靶向蛋白質的化合物、其組合物、方法和用途
IL251194A0 (en) Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
HK1208476A1 (en) Anti-b7-h6 antibody, fusion proteins, and methods of using the same b7-h6
WO2015109124A3 (en) Immunomodulatory agents
SG10201909716RA (en) Modified j-chain
EP3122783A4 (en) Novel recombinant bi-functional fusion proteins, preparation and use thereof
MY191944A (en) Binding proteins and methods of use thereof
EP3155018A4 (en) Constant region antibody fusion proteins and compositions thereof
EP3256495A4 (en) Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
MX357202B (es) Composicion de particula tipo virus.
EP3551212A4 (en) NEW RECOMBINATED KLOTHO PROTEINS AND COMPOSITIONS AND METHODS INCLUDING THEM
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
IL275435A (en) TATK – CDKL5 fusion proteins, preparations, formulations, and their uses
PH12015501854A1 (en) Factor ix polypeptide formulations
NZ731491A (en) Cd83 binding proteins and uses thereof
IL270917A (en) Recombinant ROBO2 proteins, preparations, methods and their use
AU2014904235A0 (en) Fn14 binding proteins and uses thereof